Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959)
暂无分享,去创建一个
Di Dong | Jie Tian | Jun Ma | Cheng-Long Huang | D. Dong | Jun Ma | Jie Tian | Ji-Jin Yao | M. Fang | Lianzhen Zhong | Cheng-long Huang | Meng-Jie Fang | Ling-long Tang | Fan Zhang | Fan Zhang | Lian-Zhen Zhong | Ji-Jin Yao | Ying Sun | Ling-Long Tang | Ying Sun | Cheng‐long Huang
[1] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[2] Ying Sun,et al. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. , 2018, The Lancet. Oncology.
[3] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[4] Yau-Huei Wei,et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.
[5] A. Garden,et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. , 2012, The Lancet. Oncology.
[6] Rakesh K. Jain,et al. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.
[7] J. Shah,et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity‐modulated radiotherapy , 2016, Cancer.
[8] Ying Sun,et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. , 2012, The Lancet. Oncology.
[9] J. Ji,et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] Adam P Dicker,et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. , 2016, The Lancet. Oncology.
[11] Lu Tian,et al. A Simple Method for Detecting Interactions between a Treatment and a Large Number of Covariates , 2012, 1212.2995.
[12] Zaiyi Liu,et al. Pretreatment MR imaging radiomics signatures for response prediction to induction chemotherapy in patients with nasopharyngeal carcinoma. , 2018, European journal of radiology.
[13] Jiang Li,et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma , 2015, Oncoimmunology.
[14] D. Dong,et al. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy , 2018, Clinical Cancer Research.
[15] Ying Sun,et al. Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma , 2019, Clinical Cancer Research.
[16] L. Vermeulen,et al. Cancer heterogeneity—a multifaceted view , 2013, EMBO reports.
[17] Yan Li,et al. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. , 2012, Oral oncology.
[18] Ying Sun,et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long‐term results of phase 3 randomized controlled trial , 2019, International journal of cancer.
[19] Ying Sun,et al. Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy , 2017, Journal of Cancer.
[20] Y. Shih,et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. , 2014, International journal of radiation oncology, biology, physics.
[21] S. Liang,et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. , 2016, The Lancet. Oncology.
[22] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[23] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[24] M. Cronin,et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Ying Sun,et al. Tumor response to neoadjuvant chemotherapy predicts long‐term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial , 2017, Cancer.
[26] A. Jemal,et al. Global Cancer Statistics , 2011 .
[27] P. Lambin,et al. Radiomics: the bridge between medical imaging and personalized medicine , 2017, Nature Reviews Clinical Oncology.
[28] Ying Sun,et al. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials , 2018, Clinical Cancer Research.
[29] Ying Sun,et al. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[30] T. Kang,et al. A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy , 2017, Clinical Cancer Research.
[31] Steffen Löck,et al. Image biomarker standardisation initiative , 2016 .
[32] E. Stuart,et al. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.
[33] Di Dong,et al. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? , 2018, European Radiology.